3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
9
Active not recruiting
9
Completed
5
Not yet recruiting
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
111
Carboplatin
45
Nivolumab
41
Paclitaxel
34
Cyclophosphamide
32
Cisplatin
32
Gemcitabine
30
atezolizumab
27
venetoclax
25
Specimen Handling
25
Magnetic Resonance Spectroscopy
24
Pemetrexed
23
fludarabine
22
Docetaxel
22
Biopsy
22
Radiotherapy
21
Ipilimumab
21
Bevacizumab
21
Azacitidine
21
Radiosurgery
18
Dexamethasone
18
durvalumab
17
Fluorouracil
17
Cetuximab
16
fludarabine phosphate
14
Trastuzumab
14
tislelizumab
13
Leucovorin
13
Cytarabine
13
olaparib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
poly ICLC
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled